



## REGENXBIO to Present at Upcoming Investor Conferences

October 3, 2017 11:01 AM EDT

ROCKVILLE, Md., Oct. 03, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV<sup>®</sup> Technology Platform, today announced that it will present at the following October investor conferences:

### Chardon Inaugural Gene Therapy Conference

**Date:** Tuesday, October 10, 2017

**Location:** The Westin New York Grand Central Hotel

**Fireside chat:** Tuesday, October 10, 2017 at 9:30 a.m. ET

**Panel:** Gene Therapies: Pricing and Other Commercial Considerations; Tuesday, October 10, 2017 at 4:15 p.m. ET

### Jefferies Gene Therapy Technology Investor Summit

**Date:** Thursday, October 12, 2017

**Location:** The Westin New York Grand Central Hotel

**Fireside chat:** Thursday, October 12, 2017 at 3:10 p.m. ET

A live webcast of each presentation can be accessed in the Investors section of REGENXBIO's website at [www.regenxbio.com](http://www.regenxbio.com). An archived replay of each webcast will be available on the same website for approximately 30 days following the presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at each of the conferences.

### About REGENXBIO

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV<sup>®</sup> Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

### CONTACT:

#### Investors

Natalie Wildenradt, 646-681-8192

[natalie@argotpartners.com](mailto:natalie@argotpartners.com)

#### Media

Adam Pawluk, 202-591-4063

[apawluk@jpa.com](mailto:apawluk@jpa.com)



REGENXBIO Inc.